205 related articles for article (PubMed ID: 21989071)
1. Personalized cancer medicine--advances and socio-economic challenges.
Jackson DB; Sood AK
Nat Rev Clin Oncol; 2011 Oct; 8(12):735-41. PubMed ID: 21989071
[TBL] [Abstract][Full Text] [Related]
2. Conducting economic evaluation based on basket clinical trial in the area of precision medicine.
Nosrati M; Nikfar S
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):169-171. PubMed ID: 33356657
[No Abstract] [Full Text] [Related]
3. Let's Talk About Financial Toxicities.
Katz A
Oncol Nurs Forum; 2018 May; 45(3):281-282. PubMed ID: 29683119
[TBL] [Abstract][Full Text] [Related]
4. The financial hazard of personalized medicine and supportive care.
Carrera PM; Olver I
Support Care Cancer; 2015 Dec; 23(12):3399-401. PubMed ID: 26306523
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
Haslem DS; Van Norman SB; Fulde G; Knighton AJ; Belnap T; Butler AM; Rhagunath S; Newman D; Gilbert H; Tudor BP; Lin K; Stone GR; Loughmiller DL; Mishra PJ; Srivastava R; Ford JM; Nadauld LD
J Oncol Pract; 2017 Feb; 13(2):e108-e119. PubMed ID: 27601506
[TBL] [Abstract][Full Text] [Related]
6. Balancing the Economics and Ethics of Personalised Oncology.
Flaum N; Hall P; McCabe C
Trends Cancer; 2018 Sep; 4(9):608-615. PubMed ID: 30149879
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine/personalized medicine: a critical analysis of movements in the transformation of biomedicine in the early 21st century.
Iriart JAB
Cad Saude Publica; 2019 Mar; 35(3):e00153118. PubMed ID: 30916181
[TBL] [Abstract][Full Text] [Related]
8. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
9. Is Personalized Medicine Here?
Carneiro BA; Costa R; Taxter T; Chandra S; Chae YK; Cristofanilli M; Giles FJ
Oncology (Williston Park); 2016 Apr; 30(4):293-303, 307. PubMed ID: 27085327
[TBL] [Abstract][Full Text] [Related]
10. Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.
Hirsch FR; Zaric B; Rabea A; Thongprasert S; Lertprasertsuke N; Dalurzo ML; Varella-Garcia M
Am Soc Clin Oncol Educ Book; 2017; 37():403-408. PubMed ID: 28561679
[TBL] [Abstract][Full Text] [Related]
11. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
12. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
[TBL] [Abstract][Full Text] [Related]
13. Roche splashes $2.4 billion on Foundation Medicine's cancer platform.
Sheridan C
Nat Biotechnol; 2018 Sep; 36(9):779-780. PubMed ID: 30188548
[No Abstract] [Full Text] [Related]
14. One mouse, one patient paradigm: New avatars of personalized cancer therapy.
Malaney P; Nicosia SV; Davé V
Cancer Lett; 2014 Mar; 344(1):1-12. PubMed ID: 24157811
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Alternative Payment Models on Oncology Innovation and Patient Care.
Miller AM; Omenn GS; Kean MA
Clin Cancer Res; 2016 May; 22(10):2335-41. PubMed ID: 27087022
[TBL] [Abstract][Full Text] [Related]
16. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
Fugel HJ; Nuijten M; Postma M
N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and health economic challenges of personalized medicine].
Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860
[TBL] [Abstract][Full Text] [Related]
18. Some economics on personalized and predictive medicine.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Eur J Health Econ; 2015 Dec; 16(9):985-94. PubMed ID: 25381039
[TBL] [Abstract][Full Text] [Related]
19. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.
Ling DI; Lynd LD; Harrison M; Anis AH; Bansback N
J Comp Eff Res; 2019 Jan; 8(1):7-19. PubMed ID: 30525982
[TBL] [Abstract][Full Text] [Related]
20. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
